Antibody Therapeutics Receives First Impact Factor (4.5)

Antibody Therapeutics, published by Oxford University Press, announces its inaugural Impact Factor of 4.5 from Clarivate Analytics in the latest Journal Citation Report (JCR).

This achievement underscores the journal's growing influence in antibody engineering and antibody-based therapies. We thank our authors, readers, reviewers, editors, editorial board members, and Oxford University Press for their support.